TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pro Medicus Limited ( (AU:PME) ) just unveiled an announcement.
Pro Medicus Limited reported a successful year both operationally and financially, attributing its achievements to its robust business model and the dedication of its staff. The company secured several new contracts, including its largest to date with Trinity Health, and continues to expand its product offerings through strategic acquisitions and licensing, strengthening its market position in North America and Germany.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited operates in the healthcare technology industry, offering a suite of innovative products and services aimed at maintaining market leadership. The company focuses on providing high-quality technology solutions to healthcare providers, supported by a skilled management team and dedicated staff.
YTD Price Performance: 0.67%
Average Trading Volume: 170,664
Technical Sentiment Signal: Buy
Current Market Cap: A$26.27B
For an in-depth examination of PME stock, go to TipRanks’ Overview page.